Copyright © 2021. Inderes Oyj. All rights reserved.

Cantargia

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
15.10.
2021

Redeye comments on the positive opinion of the Committee for Orphan Medicinal Products concerning an orphan designation of nadunolimab in pancreatic cancer from yesterday. This news follows on the orphan drug designation from the FDA last month.

Muut analyysit
23.9.
2021

Redeye has a positive view of Cantargia's obtaining orphan drug status. It provides some benefits, the most important of which are described in our comment.

Muut analyysit
20.8.
2021

Q2 operating losses increased y/y, as we anticipated, due to the applied and initiated studies announced in Q2.

Muut analyysit
19.8.
2021

Cantargia reported its Q2 numbers this morning with an operating loss of SEK -86.6m, 3% less negative than our estimates and up 132% from last year (SEK -37.7m).

Muut analyysit
27.5.
2021

After Cantargia's CMD last week, the Q1 report offered few surprises. The increased operating loss versus our previous estimate was likely due to R&D investments during the quarter.

Muut analyysit
26.5.
2021

Cantargia reported their Q1 this morning with an operating loss of SEK -73.2m, 45% more than we expected (SEK -50.5m) and up 83% from last year (SEK -39.9m).

Muut analyysit
26.2.
2021

Cantargia stands well equipped for a successful 2021, in our view. The Q4 report offered few surprises and the promising interim results for CANFOUR provide a good outlook for further positive data generation. The strong cash balance also puts the company in a good position when negotiating potential commercial partnership agreements. We make no estimate revisions following the report but increase our DCF-based valuation range to SEK 54-59 (48-54) per share.

Muut analyysit
4.2.
2021

Cantargia: Edison Open House interview

Cantargia